Periodic Acid Modified ECM Materials for Bioactive Crosslinking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical products made from extracellular matrix (ECM) materials face challenges in retaining native bioactivity and remodelable properties due to crosslinking processes, which can lead to undesirable consequences such as loss of bioremodelable properties and residual toxic compounds.
Innovation Solution
The development of ECM materials modified using periodic acid or its salts to introduce non-native Schiff's base crosslinks while preserving bioactive agents like proteoglycans, growth factors, and glycosaminoglycans, maintaining the material's bioactivity and mechanical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If chemical crosslinking agents like glutaraldehyde are used to enhance mechanical strength and reduce biodegradation, then the material strength and durability are improved, but the material loses its remodelable properties and may release toxic compounds into the patient's body
Solution Approach 1:
The patent changes the chemical parameters of crosslinking by using periodic acid instead of traditional aldehyde-based crosslinkers. This chemical substitution modifies the crosslinking mechanism to form different bond types that preserve ECM bioactivity while achieving the desired mechanical enhancement and reduced toxicity
Solution Approach 2:
The patent converts the potential harm of crosslinking (which typically destroys bioactivity) into a benefit by using a specific crosslinking agent that preserves it. The periodic acid crosslinking method transforms what would normally be a destructive process into one that maintains growth factors and proteoglycans functional
2Duration of action of stationary object
If traditional crosslinking methods are used to decrease biodegradation rate, then the material durability is improved, but the remodelable properties essential for tissue integration are lost
Solution Approach 1:
The patent modifies the chemical parameters of crosslinking by using periodic acid, which creates a different crosslinking chemistry that is less disruptive to the ECM structure. This allows the material to maintain its remodelable properties while achieving the desired reduction in biodegradation rate
Solution Approach 2:
The periodic acid acts as an intermediary crosslinking agent that mediates between the conflicting requirements of durability and remodelability. It provides sufficient crosslinking to reduce biodegradation while being gentle enough to preserve the bioactive components necessary for tissue integration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in ECM materials that retain bioactivity and enhance mechanical properties, promoting tissue growth and reducing biodegradation, without the use of cytotoxic crosslinking agents like glutaraldehyde, thereby improving the safety and efficacy of medical grafts.
Implementation Method 1
an ECM material layer is modified to include non-native Schiff's base crosslinks in the ECM material, for example, within and/or between certain components of the ECM material
Implementation Method 2
the ECM material is contacted with periodic acid or a salt thereof for a period of time and under conditions effective to modify the ECM material
Data Source
AI summary
Described, in certain aspects, are medical products comprised of uniquely prepared remodelable extracellular matrix (ECM) materials retaining at least a portion of their native bioactivity. Also described are methods for forming and using such products. In one embodiment, an inventive product comprises a layer of remodelable ECM material modified through contact with periodic acid or a salt thereof. In some forms, such a modified ECM material layer includes non-native Schiff's base crosslinks within and/or between certain components of the ECM material (e.g., between two collagen molecules, two non-collagen molecules, and/or a collagen molecule and a non-collagen molecule). Other inventive products are comprised of various gels, foams, pastes, and formed, coherent, porous bodies at least containing ECM materials that have been modified in accordance with the present invention.